Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Day One Biopharmaceuticals Inc (NQ: DAWN )

12.36 -0.04 (-0.32%)
Streaming Delayed Price Updated: 1:01 PM EDT, Sep 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 399,621
Open 12.52
Bid (Size) 12.35 (1)
Ask (Size) 12.37 (2)
Prev. Close 12.40
Today's Range 12.25 - 12.77
52wk Range 10.84 - 25.77
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
The Latest Analyst Ratings for Day One Biopharmaceutical
Via Benzinga
Day One Announces Updated FIREFLY-1 Data for Tovorafenib and Completion of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire

Performance

YTD
-38.96%
-38.96%
1 Month
-8.98%
-8.98%
3 Month
+0.73%
+0.73%
6 Month
-3.06%
-3.06%
1 Year
-38.54%
-38.54%

More News

Read More
Day One Announces VRK1 License Agreement and Research Collaboration with Sprint Bioscience
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Where Day One Biopharmaceutical Stands With Analysts
Via Benzinga
Day One Reports Second Quarter 2023 Financial Results and Corporate Progress
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Analyst Ratings for Day One Biopharmaceutical
Via Benzinga
Why Day One Biopharmaceuticals Stock Is Trading Higher Premarket Today
Via Benzinga
$3.6 Bet On Asana? Check Out These 4 Stocks Insiders Are Buying
Via Benzinga
Day One Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Stock Market Rally Broadens Out; Apple Unveils Vision Pro, SEC Sues Binance, Coinbase: Weekly Review
Via Investor's Business Daily
Day One Announces Pricing of Public Offering of Common Stock
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Day One Announces Proposed Public Offering of Common Stock
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Why Amedisys Shares Are Trading Higher By 14%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Why Shares of Day One Pharmaceuticals Are Up Monday
Via The Motley Fool
ImmunoGen, Day One Surge On Cancer Drug Updates, But Arcus Crashes
Via Investor's Business Daily
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Why Mallinckrodt Shares Are Trading Lower By 20%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Via InvestorPlace
Day One Biopharmaceuticals, ImmunoGen And Other Big Stocks Moving Higher In Monday's Pre-Market Session
Via Benzinga
Day One Announces New FIREFLY-1 Data for Tovorafenib (DAY101) and Initiation of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Neurofibromatosis Treatment Market Value Expected to Reach $27 Billion By End Of 2029
Via FinancialNewsMedia
Day One to Participate in the Goldman Sachs 44th Annual Healthcare Conference
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Promising Developments Announced Ahead of 2023 ASCO Annual Meeting’s Oral Presentations
Via FinancialNewsMedia
Exposures Product Safety
CORRECTION -- Day One Announces Tovorafenib (DAY101) Data and Additional Abstracts to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Day One Announces Tovorafenib (DAY101) Data and Additional Abstracts to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.